Loading
Sentiment · FY2026 Q1
What companies say about each other on earnings calls — extracted verbatim from public transcripts. Mentions from the newest quarter are a Pro feature.
“We continued to advance our NAMS capabilities with the planned acquisition of PathoQuest, which is expected to close within the next month.”
Charles River is acquiring PathoQuest, a longtime biologics-testing partner whose next-gen sequencing platform expands its non-animal (NAMS) quality-control capabilities.
“KF, the acquisition of which has already closed, has been a long-time NHP supplier in Cambodia and will further strengthen and secure our DSA supply chain.”
Charles River closed the acquisition of KF, a long-time Cambodian NHP supplier, to internalize its primate supply chain and lower DSA sourcing costs.
“Before I turn it over to Flavia, I would also like to discuss this morning's announcement regarding our actions to enhance value creation opportunities at the company in conjunction with our new shareholders, Elliott Investment Management.”
Activist investor Elliott Investment Management took a stake in Charles River, gaining four new board seats and prompting a Board strategic review to evaluate options to unlock shareholder value.
Charles River posted a fourth quarter of revenue declines with $994.2M in Q4 revenue down 2.6% organically, as DSA, RMS, and Manufacturing all contracted. Non-GAAP EPS fell 10.2% to $2.39, pressured by DSA margin compression of 460 basis points from elevated NHP sourcing costs and staffing. The forward picture brightened considerably, with DSA net book-to-bill surging to 1.12x on $665M in net bookings fueled by record $28B biotech funding in Q4. Management introduced FY2026 guidance of organic revenue flat to down 1% and non-GAAP EPS of $10.70-$11.20, signaling a return to earnings growth driven by KF Cambodia acquisition savings and $100M in incremental cost efficiencies.
Demand | Revenue Growth | Margin | Competitive Dynamics | Cost Pressure | Regulation Policy | M&A | Pricing | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 8 | 3 | 4 | 2 | 1 | 3 | 4 | 4 |
| 2025Q1 | 11 | 8 | 1 | 6 | 2 | 7 | 2 | 2 |
| 2025Q2 | 13 | 8 | 4 | 1 | 2 | 2 | 1 | |
| 2025Q3 | 10 | 4 | 3 | 3 | 4 | 3 | 3 | 1 |
| 2025Q4 | 9 | 3 | 2 | 5 | 3 | |||
| 2026Q1 | 11 | 1 | 3 | 3 | 3 | 2 | 1 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | |
|---|---|---|---|---|---|---|
| Demand | 8 | 11 | 13 | 10 | 9 | 11 |
| Revenue Growth | 3 | 8 | 8 | 4 | 1 | |
| Margin | 4 | 1 | 4 | 3 | 3 | 3 |
| Competitive Dynamics | 2 | 6 | 1 | 3 | 2 | 3 |
| Cost Pressure | 1 | 2 | 2 | 4 | 5 | 3 |
| Regulation Policy | 3 | 7 | 2 | 3 | ||
| M&A | 4 | 2 | 3 | 3 | 2 | |
| Pricing | 4 | 2 | 1 | 1 | 1 |
| Analyst | Firm | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Patrick Donnelly | Citigroup | 12 (8%) |
| Dave Windley | Jefferies | 11 (18%) |
| Max Smock | William Blair |
| Justin Bowers | Deutsche Bank | 8 (0%) |
| Mike Ryskin | Bank of America | 8 (0%) |
| Elizabeth Anderson | Evercore ISI | 8 (13%) |
| Charles Rhyee | TD Cowen | 7 (0%) |
| Eric Coldwell | Robert W. Baird | 7 (0%) |
| Casey Woodring | JPMorgan | 6 (0%) |
| Ann Hynes | Mizuho Securities | 6 (17%) |
| Firm | Analysts | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Jefferies | 2 | 13 (15%) |
| Citigroup | 1 | 12 (8%) |
| William Blair | 2 | 10 (10%) |
| TD Cowen | 2 | 9 (0%) |
| Deutsche Bank | 1 | 8 (0%) |
| Evercore ISI | 1 | 8 (13%) |
| Bank of America | 1 | 8 (0%) |
| JPMorgan | 2 | 8 (0%) |
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
CRL Charles River Laboratories | 4 | +1.2% | |
| A Agilent Technologies | 8 | +10.0% | |
| DGX Quest Diagnostics | 9 | +9.2% | |
| DHR Danaher Corporation | 7 | +3.7% | |
| IDXX Idexx Laboratories | 8 | +14.3% | |
| IQV IQVIA | 7 | +8.4% | |
| LH LabCorp | 8 | +5.8% | |
| MTD Mettler Toledo | 7 | +7.2% | |
| RVTY Revvity | 5 | +7.0% | |
| TMO Thermo Fisher Scientific | 7 | +6.2% | |
| WAT Waters Corporation | 9 | +91.5% |